Skip to main content
Evidence Snapshot

Cholinesterase

CHEMBL1914 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:55Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1914
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Cholinesterase as ChEMBL target CHEMBL1914, mapped to UniProt P06276. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Cholinesterase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1914
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P06276
Cholinesterase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Cholinesterase matters

As of 2026-09-13

Cholinesterase is reviewed as Cholinesterase (UniProt P06276); the current evidence base includes 21 approved drugs, 5690 compounds, and 997 assays, with lead potency reaching pChEMBL 10.9.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 21 approved drugs, 5690 compounds, and 997 assays for this target. The dominant activity type is IC50. CHEMBL4080419 is the current potency anchor at pChEMBL 10.9.

Use CHEMBL4080419 as the tractability anchor when discussing potency (pChEMBL 10.9).

Activity source · ChEMBL 36 via Core Engine
21 approved pChEMBL 10.9
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Cholinesterase matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P06276, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

5690
Total Compounds
997
Total Assays
21
Approved Drugs
IC50: 5383.0, KI: 567.0, EC50: 3.0, KD: 4.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4080419
 10.9 Ki —
No preferred name
CHEMBL1814730
 10.7 IC50 —
No preferred name
CHEMBL95
 10.6 IC50 Approved
No preferred name
CHEMBL224336
 10.5 IC50 —
No preferred name
CHEMBL1814731
 10.4 IC50 —

Approved Drugs

Structure Compound First Approval
NEOSTIGMINE METHYLSULFATE
CHEMBL211471
 2013
GALANTAMINE
CHEMBL659
 2001
RIVASTIGMINE
CHEMBL636
 1998
DONEPEZIL
CHEMBL502
 1996
TACRINE
CHEMBL95
 1993
TACRINE HYDROCHLORIDE
CHEMBL1677
 1993
ETHOPROPAZINE
CHEMBL1206
 1982
PYRIDOSTIGMINE BROMIDE
CHEMBL812
 1955
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:55Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1914